A phase I study to evaluate safety, pharmacokinetics, and pharmacodynamics of respiratory syncytial virus neutralizing monoclonal antibody MK‐1654 in healthy Japanese adults

Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection among all infants worldwide and remains a significant cause of morbidity and mortality. To address this unmet medical need, MK‐1654, a half‐life extended RSV neutralizing monoclonal antibody, is in clinical d...

Descripción completa

Detalles Bibliográficos
Autores principales: Orito, Yuji, Otani, Naoyuki, Matsumoto, Yuki, Fujimoto, Katsukuni, Oshima, Nobuyuki, Maas, Brian M., Caro, Luzelena, Aliprantis, Antonios O., Cox, Kara S., Tokumaru, Osamu, Kodama, Masaaki, Kudo, Hideo, Imai, Hiromitsu, Uemura, Naoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283748/
https://www.ncbi.nlm.nih.gov/pubmed/35506164
http://dx.doi.org/10.1111/cts.13290

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283748/
https://www.ncbi.nlm.nih.gov/pubmed/35506164
http://dx.doi.org/10.1111/cts.13290

Ejemplares similares